.png){kind=icon}
返回
Methicillin-Resistant Staphylococcus aureus: An Evolving Pathogen
.png){kind=icon}
OA
AI
DOI：10.1093/cid/cit613.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
The horizontal transmission of methicillin resistance to Staphylococcus aureus (MRSA) in hospital and community settings, and growing prevalence of these strains, presents a significant clinical challenge to the management of serious infections worldwide. While infection control initiatives have stemmed the rising prevalence, MRSA remains a significant pathogen. More recently, evidence that MRSA is becoming resistant to glycopeptides and newer therapies raises concern about the use of these therapies in clinical practice. Vancomycin resistance has become evident in select clinical settings through rising MICs, growing awareness of hetero-resistance, and emergence of intermediate-resistant and fully resistant strains. While resistance to linezolid and daptomycin remains low overall, point mutations leading to resistance have been described for linezolid, and horizontal transmission of cfr-mediated resistance to linezolid has been reported in clinical isolates. These resistance trends for newer therapies highlight the ongoing need for new and more potent antimicrobial therapies.
Keyword:
PANTON-VALENTINE LEUKOCIDIN
MINIMUM INHIBITORY CONCENTRATION
HOSPITAL-ACQUIRED PNEUMONIA
SOFT-TISSUE INFECTIONS
VANCOMYCIN-INTERMEDIATE
ANTIMICROBIAL RESISTANCE
REDUCED SUSCEPTIBILITY
CLINICAL-SIGNIFICANCE
GENETIC-ANALYSIS
STRAINS
期刊
IF:
7.3
论文数:
2.6W
被引数:
7.8W
机构
引用论文
The role of low dosage prothionamide with and without 4,4'-diaminio dipheimyl sulphone for use with isoniazld in the treatment of experimental mouse tuberculosis低剂量丙硫异烟胺与或无4,4'-二氨基二苯砜联合异烟肼用于实验性小鼠结核病治疗的疗效研究.png)
Tubercle
TubercleIF0
PREAI
分享收藏
查看更多内容